跳至主要内容
临床试验/NCT05719194
NCT05719194已完成不适用

Effect of a Personalized Weaning Strategy on Weaning Success

University Hospital, Clermont-Ferrand9 个研究点 分布在 1 个国家目标入组 691 人开始时间: 2023年3月14日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
691
试验地点
9
主要终点
Mortality at day 28, reintubation at 72 hours, ventilatory free days (VFDs) from first spontaneous breathing trial to day 28.

研究概览

简要总结

Weaning from mechanical ventilation is a daily challenge in intensive care units, as it can take up to 50% of the total duration of ventilation. The longer the duration of ventilation is, the more there is complication related with it.

Even when the spontaneous breathing trial is succeeded, 10 to 20% of extubations are failed and requires re-intubation.

There is two different ways to assess if the patient is capable of breathing by its own : T-piece which can be considered as hard to succeed (it can delay extubation for some patients) or pressure support ventilation with no PEEP which can be too easy and lead to an extubation too early.

Studies have identified risk factors of weaning induced pulmonary oedema wich is one of the main cause of failed extubation (up to 60%).

The purpose of P-WEAN is to evaluate whether a personalized strategy for weaning from mechanical ventilation, including daily search for weaning criteria and individualization of the weaning modality (T-piece or pressure support ventilation with zero PEEP) based on the existence of WIPO risk factors (obesity, COPD, heart disease) improves weaning success compared with usual practice.

详细描述

Before the study begin, all participating centers will be randomized to determine the time between the control and the interventional period. Patients included in the study will not be randomized individually but will be managed either according to the standard of care of the service or according to the personalized strategy (according to the stepped wedge group of the center).

  • Control period: Patients will be subjected to a weaning strategy in accordance with the usual care practices of the service (evaluation of the criteria of weanability, the modalities of the spontaneous breathing trial and extubation)
  • Interventional period: Patients will undergo a protocolized and standardized weaning strategy, including a daily assessment of weaning criteria, and a weaning trial (PSV or T-piece) whose modalities will be defined by the presence or the absence of weaning induced pulmonary oedema risk factors. These are :
  • Obesity defined as BMI greater than 30 kg/m²
  • Suspected or known COPD
  • Heart disease whether it is structural (hypertrophic, dilated, valvular), functional (diastolic or systolic dysfunction), ischemic, or dysrhythmic.

Step 1 :

Daily assessment of weaning criteria in accordance with the study protocol

Step 2 :

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Sequential
主要目的
Other
盲法
Single (Outcomes Assessor)

盲法说明

Double blind is not possible as this study evaluate a care strategy. However, in order to limit evaluation bias, the methodologist will be blinded to the group.

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •all patients ≥ 18 y.o admitted to the ICU, under invasive mechanical ventilation for more then 24 hours and fullfilling the following weaning criteria :
  • •Resolution or improvement of the condition that led to intubation, as judged by the clinician in charge of the patient.
  • •Hemodynamic stability, defined as systolic blood pressure between 90 and 160 mmHg, heart rate less than 140 beats/min, without or with low doses of vasopressors.
  • •Glasgow score of 13 or greater and Richmond Agitation-Sedation Scale (RASS) score between -1 and +
  • •Respiratory stability defined as: oxygen saturation > 90% with inspired oxygen fraction ≤ 0.5 and PEEP ≤ 8 cmH2O, respiratory rate < 35/min, spontaneous tidal volume > 5 mL/kg, and peak inspiratory pressure ≤ 15 cmH2O.
  • •Few secretions (< 3 aspirations in the past 8 hours).
  • •Effective cough.
  • •Negative leak test (>100 mL or >10%).
  • •No surgery planned within 72 hours.
  • •Patients with a social security plan.

排除标准

  • •Acute cerebral pathology requiring admission to intensive care and/or mechanical ventilation with tracheal intubation for neurological reasons (Glasgow score <13 at the time of intubation or CT scan abnormality): hemorrhagic stroke without or with vascular malformation (aneurysm, arterio-venous malformation...), ischemic stroke, head trauma, cerebral anoxo-ischemia after cardiac arrest.
  • •Tetraplegic or paraplegic patients with lesion level higher than D
  • •Peripheral neuromuscular pathology (underlying myopathy or myasthenia).
  • •ICU's Neuromyopathy.
  • •Tracheostomy.
  • •Patients with a decision of non-reintubation or terminal intubation.
  • •Pregnant or lactating women.
  • •Patients already included in this study.
  • •Patients under guardianship, curatorship or safeguard of justice.

研究组 & 干预措施

Standard intervention

Active Comparator

干预措施: Standard SBT (Other)

Personalized intervention - WIPO risk factors vs no risk factors

Experimental

干预措施: SBT with T-piece or PSV (Other)

结局指标

主要结局

Mortality at day 28, reintubation at 72 hours, ventilatory free days (VFDs) from first spontaneous breathing trial to day 28.

时间窗: 28 days

Composite score including those three criteria such that mortality is a more severe outcome than reintubation and the number of VFDs, and reintubation is a more severe outcome than the number of VFDs

次要结局

  • Mortality of ICU stay/hospital stay.(90 days)
  • Rate of extubation success after the first SBT.(72 hours from first SBT)
  • Rate of reintubation(72 hours from extubation)
  • Reintubation rate within 7 days of extubation.(7 days after extubation)
  • Time from first SBT to extubation.(28 days)
  • SBT failure rate(28 days)
  • Number of days without mechanical ventilation(From day one of first SBT to day 28)
  • Length of stay in the ICU and in the hospital.(90 days)
  • Mortality at day 28.(28 days)
  • Mortality at day 90.(90 days)
  • Rate of reintubation(72 hours from first SBT)

研究者

发起方
University Hospital, Clermont-Ferrand
申办方类型
Other
责任方
Sponsor

研究点 (9)

Loading locations...

相似试验